Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q4 2014 · —
Revenue$7.31B$7.31B+134.4% vs Q4 2013 Net Income$3.49B$3.49B+340.8% vs Q4 2013 EPS Diluted$2.18$2.18+363.8% vs Q4 2013 Gross Profit$6,159,000,000+181.9% Operating Incomederived$4,330,000,000+261.7% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,021,000,000+315.7% Free Cash Flowderived$2,854,000,000+299.7% Margins · derivedGross margin84.2%+14.2 pt vs Q4 2013
Operating margin59.2%+20.8 pt vs Q4 2013
Net margin47.7%+22.3 pt vs Q4 2013